Scholarlink

<p>This study aimed to evaluate the outcomes of patients with advanced renal cell carcinoma (aRCC) who were histologically diagnosed with non-clear cell carcinoma (nccRCC) and received combination immunotherapy. Oncological outcomes were compared between patients with non-clear cell RCC (nccRCC group) and those with clear cell RCC (cc-RCC group) who received either immune checkpoint inhibitor (ICI) + ICI combination therapy (ICI + ICI) or ICI + tyrosine kinase inhibitor (TKI) therapy (ICI + TKI). This retrospective study analyzed patients with aRCC who received combination immunotherapy as first-line treatment at 12 institutions between August 2018 and November 2023. The primary endpoint was the comparison of overall survival (OS) between the nccRCC and cc-RCC groups. The secondary endpoints included progression-free survival (PFS) and objective response rate (ORR) in both groups. The median follow–up periods for the nccRCC and cc-RCC groups were 17.7 and 20.4 months, respectively. The median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (27.8 months vs. 62.8 months; p &lt; 0.001). The ORRs in the nccRCC and cc-RCC groups were 52.4% and 63.6%, respectively. Among patients treated with ICI + ICI, the median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (23.5 months vs. 62.8 months; p &lt; 0.001). In the current era of ICI treatment, patients with nccRCC exhibit poorer oncological outcomes than those with cc-RCC. Indications should be evaluated thoroughly before selecting ICI + ICI treatment combinations for these patients. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月10日

查看全文
  • Koji Iinuma,
  • Yuta Sano,
  • Kohei Nishikawa,
  • Tomoki Taniguchi,
  • Aika Matsuyama,
  • Kaori Ozawa,
  • Takashi Ishida,
  • Kosuke Tochigi,
  • Masataka Tamura,
  • Yasuaki Kubota,
  • Shusuke Akamatsu,
  • Takahiro Inoue,
  • Takuya Koie

摘要

This study aimed to evaluate the outcomes of patients with advanced renal cell carcinoma (aRCC) who were histologically diagnosed with non-clear cell carcinoma (nccRCC) and received combination immunotherapy. Oncological outcomes were compared between patients with non-clear cell RCC (nccRCC group) and those with clear cell RCC (cc-RCC group) who received either immune checkpoint inhibitor (ICI) + ICI combination therapy (ICI + ICI) or ICI + tyrosine kinase inhibitor (TKI) therapy (ICI + TKI). This retrospective study analyzed patients with aRCC who received combination immunotherapy as first-line treatment at 12 institutions between August 2018 and November 2023. The primary endpoint was the comparison of overall survival (OS) between the nccRCC and cc-RCC groups. The secondary endpoints included progression-free survival (PFS) and objective response rate (ORR) in both groups. The median follow–up periods for the nccRCC and cc-RCC groups were 17.7 and 20.4 months, respectively. The median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (27.8 months vs. 62.8 months; p < 0.001). The ORRs in the nccRCC and cc-RCC groups were 52.4% and 63.6%, respectively. Among patients treated with ICI + ICI, the median OS was significantly shorter in the nccRCC group compared to the cc-RCC group (23.5 months vs. 62.8 months; p < 0.001). In the current era of ICI treatment, patients with nccRCC exhibit poorer oncological outcomes than those with cc-RCC. Indications should be evaluated thoroughly before selecting ICI + ICI treatment combinations for these patients.